CORONA Remedies FY26 PAT Up 33.4% on 17.3% Revenue Growth

CORONA Remedies reported 17.3% YoY revenue growth to ₹1,403.2 Cr and 33.4% PAT growth to ₹199.4 Cr in FY26.
The company acquired WOKADINE to enter ₹648 Cr Povidone Iodine market and relaunched key brands in women's health.
EBITDA margin expanded 85 bps to 20.9% in FY26 while Q4 margin contracted 89 bps due to one-time labor code impact.
Company improved market ranking to 27th position with two brands crossing ₹100 Cr MAT revenue milestone.